Corvus Pharmaceuticals (CRVS) Depreciation & Amortization (CF) (2015 - 2026)

Corvus Pharmaceuticals' Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $29000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 31.82% year-over-year to $29000.0 in Q1 2026; TTM through Mar 2026 was $112000.0, a 33.33% increase from a year earlier, with the FY2025 full-year figure at $105000.0, up 23.53% from the prior year.
• Depreciation & Amortization (CF) improved to $29000.0 in Q1 2026 per CRVS's latest filing, from $26000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $94000.0 in Q3 2022 and bottomed at $20000.0 in Q4 2024.
• The 5-year median for Depreciation & Amortization (CF) is $29000.0 (2025), against an average of $43352.9.
• Across the five-year window, Depreciation & Amortization (CF) tumbled 70.21% in 2023 and surged 38.1% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $94000.0 in 2022, then tumbled by 70.21% to $28000.0 in 2023, then decreased by 28.57% to $20000.0 in 2024, then rose by 30.0% to $26000.0 in 2025, then climbed by 11.54% to $29000.0 in 2026.
• Per Business Quant, the three latest CRVS Depreciation & Amortization (CF) figures stand at $29000.0 (Q1 2026), $26000.0 (Q4 2025), and $28000.0 (Q3 2025).